NCT03712930View on ClinicalTrials.gov

Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency

PHASE2TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

February 5, 2019

Primary Completion Date

August 6, 2020

Study Completion Date

September 2, 2020

Conditions
Metastatic Castration-Resistant Prostate Cancer (mCRPC)Homologous Recombination Deficiency (HRD)
Interventions
DRUG

Pamiparib

60 mg orally twice daily (BID)

Trial Locations (9)

935

Pan American Oncology Trials, LLC, Rio Piedras

2170

Liverpool Hospital, Liverpool

2250

Gosford Hospital, Gosford

2298

Calvary Mater Newcastle, Waratah

8035

L Hospitalet de Llobregat, Barcelona

10461

Montefiore Einstein Cancer Center, The Bronx

30607

University Cancer and Blood Center, Athens

98195

University of Washington, Seattle

044101

Icon Cancer Care Foundation, South Brisbane

Sponsors

Lead Sponsor

BeiGene
All Listed Sponsors
lead

BeiGene

INDUSTRY

NCT03712930 - Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | Biotech Hunter | Biotech Hunter